Honeysuckle-derived exosome-like nanovesicles ameliorate metabolic-associated fatty liver disease by modulating gut microbiota and its metabolites

作者：Ping Li, Qingyuan Wu, Yuanhao Zhou, Xiaojuan Hu, Yan Tang, Yuan-yuan Wang, Weijiao Fan, Yiyi Shan, Kexin Yu, Jie Wang, Shibing Wang, Ye Xiao, Huiyu Liu, Xiaozhou Mou · 发表于：Nano Research · 年份：2025 · DOI：10.26599/nr.2025.94907986 · 被引用次数：7 · 研究领域：Liver Disease Diagnosis and Treatment

Metabolic-associated fatty liver disease (MAFLD), a global health burden with limited therapeutic options beyond lifestyle changes, urgently needs novel strategies. We engineered exosome-like nanovesicles (HNVs) from dried honeysuckle ( Lonicera japonica ), exhibiting significantly more uniform size distribution than conventional herbal extracts and characteristic nanovesicle morphology. Orally delivered HNVs, enriched with bioactive metabolites, dramatically inhibited increased fat vacuoles, lipid droplet deposition, and collagen fibrosis in the livers of mice with MAFLD induced by high-fat diet (HFD). Mechanistically, HNVs orchestrate a dual gut-liver intervention: (1) Restoring gut barrier integrity, slashing serum LPS by 1.58-fold and quelling hepatic inflammation; (2) Remodeling gut microbiota to suppress bile salt hydrolase (BSH), elevating taurochenodeoxycholic acid (TCDCA) 2.07-fold. This microbial shift reprograms enterohepatic signaling by inhibiting the FXR-FGF15-FGFR4 axis, thereby boosting hepatic cholesterol catabolism via bile acid synthases. Critically, efficacy is strictly microbiota-dependent: abolished by antibiotics and fully transferable via fecal microbiota transplantation (FMT) from HNV-treated donors. Presenting the first natural nanovesicle platform that concurrently targets gut barrier repair and metabolic reprogramming, HNVs establish a pioneering, multi-targeted th...